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Abstract: The natural course of heart failure with decreased and preserved systolic function 
is almost identical. The current concept of heart failure where decreased cardiac output plays 
the major role does not explain this similarity. We suggest a revised concept of heart failure 
where congestion plays the leading role. While congestion is almost invariably present in heart 
failure with normal and with reduced systolic function, the low output syndrome is only present 
in heart failure with reduced systolic function. The small difference in morbidity and mortality 
in favor of heart failure with preserved systolic function reflects the contribution of low output 
syndrome to the natural course of the disease. Congestion can result from low output or from 
multiple other conditions, but severity of congestion is the major determinant of progression 
of heart failure.
Keywords: heart failure, congestion, ejection fraction
Background
Heart failure is a final common pathway of practically all cardiac diseases, includ-
ing coronary artery disease, hypertension, congenital cardiac defects, nonischemic 
cardiomyopathy, valvular defects of multiple etiologies, and infiltrative diseases. 
Surprisingly, the very term “heart failure” is not well defined. Multiple definitions 
circulating in the literature are inconsistent, and such inconsistency reflects the 
lack of uniform understanding of the essence of this condition. Figure 1 pres-
ents the classic chart of pathogenesis of heart failure. Decreased cardiac output 
triggers a cascade of neurohormonal activation that occupies center stage, with 
congestion being a modest byproduct of the chain of events. If this chart reflects 
the true picture, and decreased myocardial contractility plays the leading role, 
the mainstay of heart failure treatment should be inotropes. However, inotropes 
have a very limited place in management of heart failure. Besides, the chart 
does not apply to approximately one half of those patients with heart failure 
who have heart failure with preserved systolic function. These patients do not 
benefit from neurohormonal blockade, inotropes, ventricular assist devices, or 
cardiac transplantation. Most importantly, the natural course and prognosis in 
heart failure with preserved and with reduced systolic function is nearly identi-
cal. In other words, whether the pathogenetic mechanism in Figure 1 applies or 
not, the outcome is the same. There can be only one explanation, ie, decreased 
cardiac output does not play a key role in heart failure, and our current concept 
should be revised.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Guidelines on definition  
of heart failure
The European Congress of Cardiology (2008) defines heart 
failure as a “syndrome in which the patients should have 
the following features: symptoms of HF, typically shortness 
of breath at rest or during exertion, and/or fatigue; signs 
of fluid retention such as pulmonary congestion or ankle 
swelling”.1
The American College of Cardiology and the American 
Heart Association (2009) guidelines define heart failure as a 
“complex clinical syndrome … . The cardinal manifestations 
of HF are dyspnea and fatigue, which may limit exercise 
tolerance, and fluid retention, which may lead to pulmonary 
congestion and peripheral edema”.2
The  Heart  Failure  Society  of America  (2010) 
defines heart failure as “a syndrome caused by cardiac 
dysfunction … whether the dysfunction is primarily sys-
tolic or diastolic or mixed, it leads to neurohormonal and 
circulatory abnormalities, usually resulting in characteristic 
symptoms such as fluid retention, shortness of breath, and 
fatigue, especially on exertion”.3
In summary, all definitions agree that heart failure is a 
syndrome that clinically manifests itself as congestion. This 
part of all the above texts is strong and clear and obviously 
does not cause any controversies. The second part of all the 
definitions is vague and controversial.
According to the American College of Cardiology and 
the American Heart Association definition, the syndrome of 
congestion “... can result from any structural or functional 
cardiac disorder that impairs the ability of the ventricle to 
fill with or eject blood”.2 The ability of the ventricle to fill 
with blood reflects its diastolic function. The ability of the 
ventricle to eject blood reflects its systolic function.
Systolic function is measured by left ventricular ejection 
fraction using echocardiography or other imaging modali-
ties, or by cardiac output using a Swan-Ganz catheter. There 
is plenty of evidence that 40%–50% of patients with heart 
failure have normal systolic function. It was once believed 
that although left ventricular ejection fraction is preserved, 
“effective blood flow” can be impaired.4 However, several 
studies have demonstrated that blood flow is normal or 
increased in a substantial number of patients with heart failure 
with preserved systolic function.5,6
Diastolic function, or left ventricular filling pressure, is 
evaluated by echocardiography or by Swan-Ganz catheter. 
There is very little evidence that diastolic function is normal 
in any substantial proportion of the heart failure population. 
In heart failure patients with both reduced and with preserved 
left ventricular ejection fraction, diastolic dysfunction by 
echocardiography was present in more than 90% of cases.7 
None of the heart failure patients with ejection fraction less 
than 35% had normal diastolic function.8 In the Olmstead 
County heart failure cohort, only 10% of patients with 
preserved ejection fraction and 5% of patients with reduced 
ejection fraction had normal diastolic function.9 In another 
cohort, only one in 45 participants with heart failure had 
normal diastolic function.
Diastolic dysfunction, unlike systolic dysfunction, 
reflects severity of congestion. One of the parameters of 
diastolic function, namely the E/e′ ratio, correlates closely 
with intracardiac filling pressures.10–17 Simple volume over-
load with intravenous saline creates gradual progression of 
diastolic filling pattern from normal to restrictive.18
While systolic dysfunction may or may not be present in 
heart failure, diastolic dysfunction is mandatory. Diastolic 
dysfunction is the equivalent of congestion. Diastolic dys-
function is the common denominator of heart failure. There 
is no heart failure without congestion. There is no heart 
failure without diastolic dysfunction. Diastolic function 
may improve and become normal as a result of treatment or 
natural evolution of the disease, but if there is no congestion, 
no diastolic dysfunction, and no elevated left ventricular end 
diastolic pressure at any time, there is no basis for a diagnosis 
of heart failure. Therefore, it is incorrect to state that heart 
failure results from either/or the inability of the ventricle to 
fill with or eject blood. It always results from the inability of 
the ventricle to fill with blood, while the function of ejection 
may be normal or impaired. Inability of the left ventricle 
to eject blood is important to the degree of the severity of 
congestion resulting from it.
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Congestion in natural history of heart failure
According to the Heart Failure Society of America 
definition, the syndrome of congestion is “caused by cardiac 
dysfunction, generally resulting from myocardial muscle 
dysfunction or loss and characterized by either LV dilation 
or hypertrophy or both. Whether the dysfunction is primarily 
systolic or diastolic or mixed, it leads to neurohormonal and 
circulatory abnormalities …”.3
The issue with primarily systolic or diastolic dysfunction 
or mixed is analyzed above. Neurohormonal abnormalities 
are well documented in heart failure with systolic dysfunc-
tion but not with preserved systolic function. All attempts 
to treat heart failure with preserved systolic function using 
medications targeting neurohormonal changes have failed. 
The CHARM-Preserved (Candesartan in Heart Failure 
Assessment of Reduction in Mortality and Morbidity) trial 
randomized 3023 patients between candesartan and placebo19 
and failed to demonstrate a significant effect on cardiovas-
cular death, but fewer heart failure hospitalizations in the 
candesartan-treated patients were observed. These results 
are difficult to interpret because the cutoff of left ventricular 
ejection fraction in the CHARM trial was 40%, which cre-
ates a mix of heart failure with normal systolic function and 
with mild systolic dysfunction. The PEP-CHF (Perindopril 
in Elderly People with Chronic Heart Failure) study showed 
no effect of perindopril on mortality and heart failure hos-
pitalizations.20 The I-PRESERVE (Irbesartan in HF with 
preserved ejection fraction) trial did not demonstrate any 
mortality or morbidity benefit from irbesartan.21 A recent 
meta-analysis22 combined these studies to increase their 
statistical power and also failed to demonstrate a significant 
effect of inhibition of the renin-angiotensin-aldosterone 
system on mortality in preserved systolic function.
The statement of left ventricular dilatation or hypertrophy 
is also soft. The left ventricle may be dilated, but it may be 
normal in size. It can be hypertrophied but may also have 
perfectly normal wall thickness.
To summarize, heart failure is a clinical syndrome of 
congestion. It may be caused by decreased systolic function 
or other conditions causing volume overload. Therefore, 
evidence of congestion should be mandatory for the diagnosis 
of heart failure.
Guidelines on evidence  
of congestion
According to ADHERE (the Acute Decompensated Heart 
Failure National Registry), which included patients with and 
without left ventricular systolic dysfunction, most patients 
admitted for heart failure are “wet” or congested, with 
  dyspnea, rales, edema, radiological signs of fluid overload, or 
combination of the above.23 However, making the diagnosis 
of heart failure with preserved systolic function by only clini-
cal criteria and normal ejection fraction could result in over-
diagnosis of this condition. In a study by Caruana et al,24 most 
patients with normal ejection fraction who were diagnosed 
as having heart failure in fact suffered from other diseases, 
such as coronary artery disease, obesity, chronic obstruc-
tive pulmonary disease, or other conditions explaining their 
symptoms, and only seven of 109 had heart failure.
To diagnose heart failure with preserved systolic function 
accurately, one has to demonstrate evidence of increased 
intracardiac pressures. Vasan and Levy proposed standardized 
clinical criteria where the diagnosis of “definite” heart failure 
requires clinical heart failure and ejection fraction $50% 
assessed within 72 hours after diagnosis and confirmed 
elevated filling pressures.25 The timing requirement was later 
found to be unnecessary, because it was shown that ejection 
fraction does not change during decompensation and remains 
relatively stable.26 The Working Group on Myocardial 
Function of the European Society of Cardiology27 required 
evidence of diastolic dysfunction (pulmonary capillary 
wedge pressure .12 mmHg or left ventricular end diastolic 
pressures .16 mmHg) provided by cardiac catheterization 
or by Doppler velocities on echocardiography.
According to the European Society of Cardiology, three 
obligatory conditions are needed for the diagnosis of heart 
failure with normal systolic function. They include the 
presence of signs or symptoms of congestive heart failure, 
ejection fraction .50%, and evidence of left ventricular 
diastolic dysfunction.28
Unfortunately, the majority of studies enrolling patients 
with heart failure and normal systolic function did not 
have documentation of either intracardiac pressure or left 
ventricular diastolic dysfunction. More importantly, not 
all current guidelines require rigorous assessment of dia-
stolic dysfunction to establish a diagnosis of heart failure. 
Meanwhile, because congestion is the essence of heart fail-
ure, whether with preserved or reduced systolic function, 
evidence of congestion should be a mandatory part of the 
assessment of patients who may have heart failure based on 
symptoms. Addressing the requirements for initial assess-
ment of patients with heart failure, American College of 
Cardiology and the American Heart Association guidelines 
recommend echocardiography for assessment of “... left 
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thickness, and valve   function ...” but do not even mention 
diastolic dysfunction.2
The easiest way to estimate intracardiac pressures is 
to measure the level of brain natriuretic peptide, but in 
the American College of Cardiology and the American 
Heart Association guidelines it is recommended only as 
a supplemental tool “to improve diagnostic accuracy”.2 
Amazingly, recommended initial laboratory evaluation of 
patients presenting with heart failure includes complete 
blood count, urinalysis, serum electrolytes (including 
calcium and magnesium), blood urea nitrogen, serum 
creatinine, fasting blood glucose, lipid profile, liver func-
tion tests, and thyroid-stimulating hormone, but not brain 
natriuretic peptide.2 In fact, brain natriuretic peptide is 
far more important for establishing the diagnosis of heart 
failure than the lipid profile, thyroid hormones, or any 
other listed parameters. On the contrary, the Heart Failure 
Society of America guidelines recommend measurement 
of brain natriuretic peptide in every patient with suspected 
heart failure.3 Similarly, European guidelines include brain 
natriuretic peptide as a mandatory step in establishing the 
diagnosis of heart failure.1
In summary, if all guidelines agree that heart failure is 
a syndrome of congestion, then evidence of congestion and 
assessment of its severity should be a cornerstone of the 
diagnosis and ongoing patient evaluation on follow-up. This 
applies similarly to heart failure with normal and reduced 
systolic function.
Low output syndrome
It is impossible to deny that not only congestion but also 
low output plays an important role in the natural history of 
heart failure, but only in heart failure with reduced systolic 
function. Multiple studies have reported decreased left 
ventricular ejection fraction as a poor predictive sign.29,30 In 
order to quantify its role and to compare it with the role of 
congestion, we have to compare the course of heart failure 
with normal and decreased systolic function.
Patients with preserved heart failure are usually older, 
more frequently women, have less coronary disease and 
myocardial infarction, and have more atrial fibrillation and 
other comorbidities. They have higher systolic blood pres-
sures and pulse pressures,29 as well as a higher prevalence 
of left ventricular hypertrophy, aortic valve disease, and 
anemia.30
Despite these dissimilarities, the reported mortality is 
either similar30–34 or somewhat better in preserved systolic 
function.35,36 Earlier studies published in the 1980s and early 
1990s reported a better prognosis in preserved ejection 
  fraction, but more recent studies have identified no differ-
ences in mortality.37
Patients with heart failure with both reduced and normal 
systolic function have congestion, but only patients with 
reduced systolic function have low output. Therefore, the 
difference in morbidity and mortality between heart failure 
with preserved and reduced left ventricular ejection frac-
tion reflects the contribution of low output syndrome to the 
natural course of heart failure. Similarities in the natural 
course of heart failure with reduced and with preserved 
systolic function are likely explained by the syndrome of 
congestion shared by both groups. Using therapies unique 
for heart failure with the component of low output, or left 
ventricular remodeling, or reduced left ventricular sys-
tolic dysfunction (beta-blockers, angiotensin-converting 
enzyme inhibitors, cardiac resynchronization therapy, 
implantable cardioverter-defibrillator devices, ventricular 
assist devices, and cardiac transplantation) we are closing 
the small gap between morbidity and mortality in heart fail-
ure with normal and decreased systolic function. To treat 
the syndrome of congestion, which determines the course 
of heart failure to a much greater degree than the syndrome 
of low output, we use diuretics. The role of diuretics in 
the treatment of heart failure is discussed elsewhere.38,39 It 
typically takes fewer than 100 patients and several weeks 
of follow-up to realize that patients with heart failure 
cannot live without them,40–43 while it took thousands of 
patients and years of follow-up to demonstrate the survival 
benefit of angiotensin-converting enzyme inhibitors or 
beta-blockers.44,45
It is difficult to imagine a patient with heart failure 
who has never experienced congestion. However, there 
are clearly symptomatic patients with heart failure who 
are not congested. They are a small subset of very sick 
patients with low output and low systolic blood pressure. 
In full agreement with the pathogenetic chart (Figure 1), 
they benefit from inotropes, an intra-aortic balloon 
pump, any means of mechanical circulation, and cardiac 
transplantation.
Inotropes were not proven to be beneficial in any of 
the randomized controlled trials, but everybody uses them 
empirically. Even if such patients are congested, they can 
rarely be diuresed without inotropes. The OPTIME-HF 
(Outcomes of Prospective Trial of Intravenous Milrinone for 
Acute Exacerbation of Chronic Heart Failure) trial unfortu-
nately was not very informative because patients requiring 
inotropic support were not included.46International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Revised concept of heart failure
In the pathogenetic scheme reflecting the true relationship of 
two major syndromes in heart failure, ie, congestion, which 
is mandatory, and low output, which is optional, congestion 
occupies central place (Figure 2).
Congestion not only causes symptoms of volume over-
load, but it also determines the prognosis.47 Congestion 
causes cardiorenal syndrome,48,49 pulmonary hypertension, 
and right ventricular failure. All of these symptoms exacer-
bate the problem, causing further congestion. Because con-
gestion plays the central role, diuretics are the only group of 
medications equally effective in heart failure with preserved 
or reduced systolic function. In inpatient or outpatient set-
tings, in systolic or diastolic heart failure, diuretics invariably 
remain the top prescribed drugs.23
In about 50% of patients with heart failure, congestion is 
caused by left ventricular systolic dysfunction. It has been 
shown that heart failure with preserved and reduced systolic 
function is typically not different stages of the same disease 
but rather separate entities. The left ventricular ejection frac-
tion has a bimodal distribution.50
However, the relationship between intracardiac   pressure 
and ejection fraction may be more complex. Evidence   suggests 
that persistence of congestion or high intracardiac pressures 
results in decreased contractility, and decongestion improves 
contractility. In animal experiments, myocardial edema 
results in an immediate decrease in contractility.51 Aggres-
sive diuresis resulted not only in decreased pulmonary 
capillary wedge pressure but also in an increase in left ven-
tricular ejection fraction from 35.7% to 39.5% in a matter 
of six days.52
Even electrical instability, which is usually a feature 
of left ventricular remodeling, may be precipitated by 
  congestion. Studies of tracings from implantable devices with 
OptiVol® indicate there is a weak but significant association 
between decreased intrathoracic impedance and malignant 
ventricular arrhythmias.53,54
The other 50% of patients with heart failure who have 
normal systolic function have congestion resulting from other 
causes, including renal dysfunction, infiltrative diseases of 
the myocardium, iatrogenic fluid overload, ischemia, hyper-
tension with left ventricular hypertrophy, or any other condi-
tions increasing intravascular volume, or altering myocardial 
relaxation. They demonstrate less electrical instability, are 
less prone to sudden cardiac death, and benefit little from 
inhibition of renin-angiotensin or beta-blockade.
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Conclusion
Heart failure is a syndrome of congestion resulting from 
decreased left ventricular systolic function or any other 
condition causing fluid retention or altering relaxation of the 
myocardium. Evidence of congestion, increased intracardiac 
pressures, or diastolic dysfunction is a mandatory step in the 
initial diagnosis of heart failure, and evaluation of severity of 
congestion is a mandatory step in all subsequent evaluation 
of patients with heart failure. Congestion is the main factor 
that determines the natural course of heart failure. The role 
of low output syndrome, or decreased systolic function, can 
be defined as the difference between morbidity and mortal-
ity in heart failure with reduced and with preserved systolic 
function. Guidelines that currently define the strategy of 
diagnosis and management of heart failure could benefit 
from revisions consistent with this concept.
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